Daijun Xing,Fuman Wang,Min Qi,Xiaokun Wang,Xu Zhu,Yufeng Cao,Zhengtong Zhao,Gaoyang Lin. EZH2 is a biomarker associated with lung cancer diagnosis and immune infiltrates without prognostic specificity: a study based on the cancer genome atlas data. Oncol Transl Med, 2023, 9: 99-114. |
EZH2 is a biomarker associated with lung cancer diagnosis and immune infiltrates without prognostic specificity: a study based on the cancer genome atlas data |
Received:October 10, 2022 Revised:May 29, 2023 |
View Full Text View/Add Comment Download reader |
KeyWord:Enhancer of zeste homolog 2; lung cancer; diagnosis; prognosis; immune infiltrating |
Author Name | Affiliation | E-mail | Daijun Xing | Cardiac Center (Department of Vascular Surgery), The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao 266033, China | | Fuman Wang | Cardiac Center (Department of Vascular Surgery), The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao 266033, China | | Min Qi | Cardiac Center (Department of Vascular Surgery), The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao 266033, China | | Xiaokun Wang | Cardiac Center (Department of Vascular Surgery), The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao 266033, China | | Xu Zhu | Cardiac Center (Department of Vascular Surgery), The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao 266033, China | | Yufeng Cao | Cardiac Center (Department of Vascular Surgery), The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao 266033, China | | Zhengtong Zhao | Cardiac Center (Department of Vascular Surgery), The Affiliated Qingdao Hiser Hospital of Qingdao University (Qingdao Hospital of Traditional Chinese Medicine), Qingdao 266033, China | | Gaoyang Lin | Department of Thoracic Surgery, The Affiliated Qingdao Hiser Medical Center of Qingdao University Medical College | lingaoyang1988@126.com |
|
Hits: 2074 |
Download times: 2762 |
Abstract: |
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2).
Dysregulation of EZH2 causes alteration of gene expression and functions, thereby promoting cancer
development. Recent studies suggest that EZH2 has a potential prognostic role in patients with nonsmall cell lung cancer (NSCLC). However, the prognostic value of EZH2 expression levels in NSCLC is
controversial. In this study, we evaluated the prognostic value in lung cancer (LC-LUAD/LUSC) based on
data from The Cancer Genome Atlas (TCGA) database. Kruskal-Wallis test, Wilcoxon signed-rank test, and
logistic regression were used to evaluate the relationship between EZH2 expression and clinicopathological
features. Cox regression and the Kaplan-Meier method were adopted to evaluate prognosis-related factors.
Gene set enrichment analysis (GSEA) was performed to identify the key pathways related to EZH2. The
correlations between EZH2 and cancer immune infiltrates were investigated by single-sample Gene Set
Enrichment Analysis (ssGSEA). EZH2 was found to be up regulated with amplification in tumor tissues
in multiple LC cohorts. High EZH2 expression was associated with poorer overall survival (OS). GSEA
suggested that EZH2 regulates innate immune system, ECM affiliated, matrisome, surfactant metabolism.
Notably, ssGSEA indicated that EZH2 expression was positively correlated with infiltrating levels of Th2
cells and significantly negatively correlated with mast cell infiltration level. These results suggest that EZH2
is associated with LC immune infiltration and significantly over-expressed in lung cancer, and its diagnostic
value is better than prognosis, which lays a foundation for further study of the immunomodulatory role of
EZH2 in LC. |
Close |
|
|
|